Pure Global AI
NCT06381960Recruiting

Clinical Study on the Prevention and Treatment of Postoperative Metastasis of Lung Cancer by Fuzheng Quxie Recipe

Clinical Study on the Prevention and Treatment of Postoperative Metastasis in Stage IIA-IIIA Lung Cancer With Negative Expression of Driver Genes by Fuzheng Quxie Recipe
Jianhui TianPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Lung Cancer
Drug/Device/Intervention
Fuzheng Quxie Recipe
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jianhui Tian
Funder
Shanghai Municipal Hospital of Traditional Chinese Medicine
Location
Changning,Hongkou,Hongkou,Jing'an,Yangpu, China
Timeline & enrollment
Phase
Phase 2
Start date
Mar 01, 2023
End date
Dec 31, 2025
Enrollment
356 participants
Primary outcome

Disease-free survival, DFS

Summary

To address the clinical challenge of postoperative metastasis in stage IIA-IIIA non-small
 cell lung cancer with negative driver gene expression, there is a lack of effective
 diagnostic and therapeutic measures. Based on this, investigators propose to carry out a
 clinical study on the prevention and treatment of postoperative metastasis of IIA-IIIA stage
 lung cancer with negative driver gene expression with the formula of supporting the positive
 and dispelling the evil.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06381960
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06381960 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jianhui Tian and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 356 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.